Inhibition of neutral sphingomyelinases in skeletal muscle attenuates fatty-acid induced defects in metabolism and stress

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-12

  Verma, Mahesh Kumar ^a   Yateesh, Aggunda Nagaraju ^a   Neelima, Korrapati ^a   Pawar, Niketa ^a   Sandhya, Kandoor ^a   Poornima, Jayaram ^a   Lakshmi, Mudigere N ^a   Yogeshwari, Sivakumaran ^a   Pallavi, Puttrevana M ^a   Oommen, Anup M ^a   Somesh, Baggavalli P ^a   Jagannath, Madanahalli R ^a  

^a Connexios Life Sciences Private Ltd ^*  (India)

Author keywords

C2C12 myotubes; Cellular stress; Ceramide; Insulin resistance; Oxidative capacity; Sphingomyelinase; T2DM

Indexed keywords

EID: 84903999673     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-255     Document Type: Article

References (64)

1. Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53: 25-31.
2. Asmann YW, Stump CS, Short KR, Coenen-Schimke JM, Guo Z, Bigelow ML, Nair KS: Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes 2006, 55: 3309-3319.
3. Baron AD, Brechtel G, Wallace P, Edelman SV: Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 1988, 255: E769-E774.
4. Blachnio-Zabielska A, Baranowski M, Zabielski P, Gorski J: Effect of high fat diet enriched with unsaturated and diet rich in saturated fatty acids on sphingolipid metabolism in rat skeletal muscle. J Cell Physiol 2010, 225: 786-791.
5. Blachnio-Zabielska AU, Koutsari C, Tchkonia T, Jensen MD: Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance. Obesity (Silver Spring) 2012, 20: 2341-2347.
6. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ, Dyck DJ: Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 2004, 18: 1144-1146.
7. Boon J, Hoy AJ, Stark R, Brown RD, Meex RC, Henstridge DC, Schenk S, Meikle PJ, Horowitz JF, Kingwell BA, Bruce CR, Watt MJ: Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscleinsulin resistance. Diabetes 2013, 62: 401-110.
8. Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP, Laville M, Le Marchand-Brustel Y, Tanti JF, Vidal H: Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 2003, 52: 1319-1325.
9. Bruce CR, Risis S, Babb JR, Yang C, Kowalski GM, Selathurai A, Lee-Young RS, Weir JM, Yoshioka K, Takuwa Y, Meikle PJ, Pitson SM, Febbraio MA: Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulinresistance in high-fat diet-fed mice. Diabetes 2012, 61: 3148-3155.
10. Bruce CR, Risis S, Babb JR, Yang C, Lee-Young RS, Henstridge DC, Febbraio MA: The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice. Endocrinology 2013, 154: 65-76.
11. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, Summers SA: A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003, 278: 10297-10303.
12. Chavez JA, Holland WL, Bär J, Sandhoff K, Summers SA: Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 2005, 280: 20148-20153.
13. De Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppänen-Laakso T, Oresic M, Pulkkinen L, Uusitupa M, Erkkilä AT: Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6concentration in patients with coronary heart disease. Diabetologia 2009, 52: 2612-2615.
14. Dobrzyń A, Górski J, Ceramides and sphingomyelins in skeletal muscles of the rat: content and composition: Effect of prolonged exercise. Am J Physiol Endocrinol Metab 2002, 282: E277-E285.
15. Goodpaster BH, Theriault R, Watkins SC, Kelley DE: Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000, 49: 467-472.
16. Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001, 86: 5755-5761.
17. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP: Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity ofinsulin resistance. Diabetes 2009, 58: 337-343.
18. He J, Watkins S, Kelley DE: Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 2001, 50: 817-823.
19. Helge JW, Dobrzyn A, Saltin B, Gorski J: Exercise and training effects on ceramide metabolism in human skeletal muscle. Exp Physiol 2004, 89: 119-127.
20. Hey-Mogensen M, Højlund K, Vind BF, Wang L, Dela F, Beck-Nielsen H, Fernström M, Sahlin K: Effect of physical training on mitochondrial respiration and reactive oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. Diabetologia 2010, 53: 1976-1985.
21. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA: Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulinresistance. Cell Metab 2007, 5: 167-179.
22. Hu W, Bielawski J, Samad F, Merrill AH Jr, Cowart LA: Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity. J Lipid Res 2009, 50: 1852-1862.
23. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51: 2005-2011.
24. Kelley DE, Mintun MA, Watkins SC, Simoneau JA, Jadali F, Fredrickson A, Beattie J, Thériault R: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996, 97: 2705-2713.
25. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51: 2944-2950.
26. Kendall MR, Hupfeld CJ: FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulinresistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes Metab 2008, 10: 802-805.
27. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB: Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 1999, 104: 733-741.
28. Kim YI, Lee FN, Choi WS, Lee S, Youn JH: Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. Diabetes 2006, 55: 2311-2317.
29. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM: Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008, 7: 45-56.
30. Krook A, Björnholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG Jr, Wallberg-Henriksson H, Zierath JR: Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 2000, 49: 284-292.
31. Kulkarni SS, Salehzadeh F, Fritz T, Zierath JR, Krook A, Osler ME: Mitochondrial regulators of fatty acid metabolism reflect metabolic dysfunction in type 2 diabetes mellitus. Metabolism 2012, 61: 175-185.
32. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE: Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003, 100: 3077-3082.
33. Long SD, Pekala PH: Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 1996, 319: 179-184.
34. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK: Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 2002, 277: 41128-41139.
35. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51: 7-18.
36. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P: Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond) 2007, 31: 1302-1310.
37. Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K: Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007, 56: 1592-1599.
38. MohammadTaghvaei N, Taheripak G, Taghikhani M, Meshkani R: Palmitate-induced PTP1B expression is mediated by ceramide-JNK and nuclear factor κB (NF-κB) activation. Cell Signal 2012, 24: 1964-1970.
39. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34: 267-273.
40. Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H: Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998, 41: 257-264.
41. Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, Schön MR, Blüher M, Punkt K: Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006, 29: 895-900.
42. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100: 8466-8471.
43. Pickersgill L, Litherland GJ, Greenberg AS, Walker M, Yeaman SJ: Key role for ceramides in mediating insulin resistance in human muscle cells. J Biol Chem 2007, 282: 12583-9.
44. Powell DJ, Turban S, Gray A, Hajduch E, Hundal HS: Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 2004, 382: 619-629.
45. Pralhada Rao R, Vaidyanathan N, Rengasamy M, Mammen Oommen A, Somaiya N, Jagannath MR: Sphingolipid metabolic pathway: an overview of major roles played in human diseases. J Lipids 2013, 2013: 178910.
46. Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, Chiarugi P: Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci 2009, 66: 3207-3218.
47. Scheffer L, Raghavendra PR, Ma J, Acharya JK: Ceramide transfer protein and cancer. Anticancer Agents Med Chem 2011, 11: 904-910.
48. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K: Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107: 3040-3046.
49. Schmitz-Peiffer C, Craig DL, Biden TJ: Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway inC2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999, 274: 24202-24210.
50. Schrauwen P, Hesselink MK: Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 2004, 53: 1412-1417.
51. Senn JJ: Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006, 281: 26865-26875.
52. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F: Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008, 283: 13538-13548.
53. Simoneau JA, Kelley DE: Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol (1985) 1997, 83: 166-171.
54. Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I, Baranowski M, Zendzian-Piotrowska M, Brzezinska Z, Gorski J: Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004, 53: 1215-1221.
55. Straczkowski M, Kowalska I, Baranowski M, Nikolajuk A, Otziomek E, Zabielski P, Adamska A, Blachnio A, Gorski J, Gorska M: Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 2007, 50: 2366-2373.
56. Szendroedi J, Schmid AI, Chmelik M, Toth C, Brehm A, Krssak M, Nowotny P, Wolzt M, Waldhausl W, Roden M: Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 2007, 4: e154.
57. Tsintzas K, Chokkalingam K, Jewell K, Norton L, Macdonald IA, Constantin-Teodosiu D: Elevated free fatty acids attenuate the insulin-induced suppression of PDK4 gene expression in human skeletal muscle: potential role of intramuscular long-chain acyl-coenzyme A. J Clin Endocrinol Metab 2007, 92: 3967-3972.
58. Turpin SM, Lancaster GI, Darby I, Febbraio MA, Watt MJ: Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulinresistance. Am J Physiol Endocrinol Metab 2006, 291: E1341-E1350.
59. Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ, Lopaschuk DG, Proctor SD, Keung W, Muoio DM, Lopaschuk GD: Inhibition ofde novoceramide synthesis reverses diet-induced insulin resistance and enhances whole-bodyoxygen consumption. Diabetes 2010, 59: 2453-2464.
60. van der Vusse GJ, Reneman RS: Lipid metabolism in muscle. In Handbook of Physiology: Exercise: Regulation and Integration of Multiple Systems. Bethesda, MD: Am. Physiol. Soc., sect. 12, chapt. 21; 1996: 952-994.
61. Watson ML, Coghlan M, Hundal HS: Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-inducedinsulin resistance in rat skeletal muscle cells. Biochem J 2009, 417: 791-801.
62. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F: Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009, 297: E211-E224.
63. Yuzefovych L, Wilson G, Rachek L: Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6skeletal muscle cells: role of oxidative stress. Am J Physiol Endocrinol Metab 2010, 299: E1096-E1105.
64. Zierath JR: The path to insulin resistance: paved with ceramides?Cell Metab 2007, 5: 161-163.